IN8bio’s (INAB) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of IN8bio (NASDAQ:INABFree Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $12.50 price objective on the stock.

Separately, Laidlaw initiated coverage on shares of IN8bio in a report on Monday, March 18th. They set a buy rating and a $7.50 target price for the company.

Get Our Latest Report on INAB

IN8bio Price Performance

IN8bio stock opened at $1.23 on Tuesday. IN8bio has a 52-week low of $0.65 and a 52-week high of $3.05. The firm has a market capitalization of $54.27 million, a price-to-earnings ratio of -1.35 and a beta of 0.14. The company has a fifty day simple moving average of $1.06 and a 200-day simple moving average of $1.17. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.02.

IN8bio (NASDAQ:INABGet Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). On average, equities analysts anticipate that IN8bio will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of INAB. AIGH Capital Management LLC acquired a new stake in shares of IN8bio during the fourth quarter worth about $5,216,000. Rock Creek Group LP increased its stake in shares of IN8bio by 98.3% during the third quarter. Rock Creek Group LP now owns 151,314 shares of the company’s stock worth $157,000 after buying an additional 75,000 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc increased its stake in shares of IN8bio by 85.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 78,624 shares of the company’s stock worth $109,000 after buying an additional 36,179 shares during the period. Institutional investors and hedge funds own 92.05% of the company’s stock.

About IN8bio

(Get Free Report)

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.

Featured Articles

Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with's FREE daily email newsletter.